{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T04:12:29Z","timestamp":1758946349225,"version":"3.44.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB TRR219"],"award-info":[{"award-number":["SFB TRR219"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010578","name":"Deutsche Gesellschaft f\u00fcr Kardiologie-Herz und Kreislaufforschung.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010578","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014941","name":"Cytokinetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.pcad.2021.02.005","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T01:20:45Z","timestamp":1613352045000},"page":"76-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["The current status of renal denervation for the treatment of arterial hypertension"],"prefix":"10.1016","volume":"65","author":[{"given":"Lucas","family":"Lauder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Mahfoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10159","key":"10.1016\/j.pcad.2021.02.005_bb0005","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/S0140-6736(18)32225-6","article-title":"Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Stu","volume":"392","year":"2018","journal-title":"Lancet"},{"issue":"10022","key":"10.1016\/j.pcad.2021.02.005_bb0010","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.pcad.2021.02.005_bb0015","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","article-title":"Global disparities of hypertension prevalence and control","volume":"134","author":"Mills","year":"2016","journal-title":"Circulation"},{"issue":"10064","key":"10.1016\/j.pcad.2021.02.005_bb0020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(16)31919-5","article-title":"Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants","volume":"389","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.pcad.2021.02.005_bb0025","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41569-020-0364-1","article-title":"Device-based therapies for arterial hypertension","volume":"17","author":"Lauder","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"9","key":"10.1016\/j.pcad.2021.02.005_bb0030","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/eurheartj\/ehs041","article-title":"The human sympathetic nervous system: its relevance in hypertension and heart failure","volume":"33","author":"Parati","year":"2012","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.pcad.2021.02.005_bb0035","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1152\/japplphysiol.00832.2009","article-title":"The 2009 Carl Ludwig lecture: pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management","volume":"108","author":"Esler","year":"2010","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.pcad.2021.02.005_bb0040","series-title":"Comprehensive Physiology","first-page":"731","article-title":"Neural control of renal function","volume":"Vol 1","author":"Johns","year":"2011"},{"issue":"3","key":"10.1016\/j.pcad.2021.02.005_bb0045","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1161\/01.HYP.0000047205.52509.8A","article-title":"Neural control of the kidney: past, present, and future","volume":"41","author":"DiBona","year":"2003","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.pcad.2021.02.005_bb0050","doi-asserted-by":"crossref","first-page":"F190","DOI":"10.1152\/ajprenal.1985.248.2.F190","article-title":"Characterization of a new model for the study of pressure-natriuresis in the rat","volume":"248","author":"Roman","year":"1985","journal-title":"Am J Physiol Physiol"},{"issue":"4","key":"10.1016\/j.pcad.2021.02.005_bb0055","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1161\/HYPERTENSIONAHA.111.00474","article-title":"Reversal of genetic salt-sensitive hypertension by targeted sympathetic ablation","volume":"61","author":"Foss","year":"2013","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.pcad.2021.02.005_bb0060","doi-asserted-by":"crossref","first-page":"R245","DOI":"10.1152\/ajpregu.00647.2009","article-title":"Translational medicine: the antihypertensive effect of renal denervation","volume":"298","author":"DiBona","year":"2010","journal-title":"AJP Regul Integr Comp Physiol"},{"issue":"8","key":"10.1016\/j.pcad.2021.02.005_bb0065","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0895-7061(02)02959-X","article-title":"Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity","volume":"15","author":"Ye","year":"2002","journal-title":"Am J Hypertens"},{"issue":"15","key":"10.1016\/j.pcad.2021.02.005_bb0070","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1161\/01.CIR.0000034043.16664.96","article-title":"Sympathetic nerve activity in end-stage renal disease","volume":"106","author":"Hausberg","year":"2002","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.pcad.2021.02.005_bb0075","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1001\/jama.1953.03690160001001","article-title":"Splanchnicectomy for essential hypertension","volume":"152","author":"Smithwick","year":"1953","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pcad.2021.02.005_bb0080","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/0002-9610(48)90284-0","article-title":"Hypertension and its surgical treatment by bilateral supradiaphragmatic splanchnicectomy","volume":"75","author":"Peet","year":"1948","journal-title":"Am J Surg"},{"issue":"5","key":"10.1016\/j.pcad.2021.02.005_bb0085","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/0021-9681(55)90061-8","article-title":"Hypertensive vascular disease","volume":"1","author":"Smithwick","year":"1955","journal-title":"J Chronic Dis"},{"issue":"6","key":"10.1016\/j.pcad.2021.02.005_bb0090","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1097\/00000658-194906000-00012","article-title":"Results of treatment of patients with hypertension by total thoracic and partial to total lumbar sympathectomy, splanchnicectomy and celiac ganglionectomy","volume":"129","author":"Grimson","year":"1949","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.pcad.2021.02.005_bb0095","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1172\/JCI100651","article-title":"A surgical treatment of essential hypertension","volume":"14","author":"Page","year":"1935","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.pcad.2021.02.005_bb0100","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/00325481.1956.11708343","article-title":"Modern therapeutic approach to malignant hypertension","volume":"19","author":"Evans","year":"1956","journal-title":"Postgrad Med"},{"issue":"11","key":"10.1016\/j.pcad.2021.02.005_bb0105","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jama.1967.03130240070013","article-title":"Effects of treatment on morbidity in hypertension","volume":"202","author":"Veterans Administration Cooperative Study Group on Antihypertensive Agents","year":"1967","journal-title":"JAMA"},{"issue":"9671","key":"10.1016\/j.pcad.2021.02.005_bb0110","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(09)60566-3","article-title":"Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study","volume":"373","author":"Krum","year":"2009","journal-title":"Lancet"},{"issue":"9756","key":"10.1016\/j.pcad.2021.02.005_bb0115","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","article-title":"Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial","volume":"376","author":"Esler","year":"2010","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.pcad.2021.02.005_bb0120","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","article-title":"A controlled trial of renal denervation for resistant hypertension","volume":"370","author":"Bhatt","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pcad.2021.02.005_bb0125","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/eurheartj\/ehu441","article-title":"Predictors of blood pressure response in the SYMPLICITY HTN-3 trial","volume":"36","author":"Kandzari","year":"2015","journal-title":"Eur Heart J"},{"issue":"9981","key":"10.1016\/j.pcad.2021.02.005_bb0130","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/S0140-6736(14)61942-5","article-title":"Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial","volume":"385","author":"Azizi","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.pcad.2021.02.005_bb0135","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/CIRCULATIONAHA.116.022922","article-title":"Adherence to antihypertensive treatment and the blood pressure\u2013lowering effects of renal denervation in the renal denervation for hypertension (DENERHTN) trial","volume":"134","author":"Azizi","year":"2016","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.pcad.2021.02.005_bb0140","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1161\/HYPERTENSIONAHA.119.13520","article-title":"Clinic versus ambulatory blood pressure in resistant hypertension: impact of antihypertensive medication nonadherence","volume":"74","author":"Hamdidouche","year":"2019","journal-title":"Hypertension"},{"issue":"33","key":"10.1016\/j.pcad.2021.02.005_bb0145","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1093\/eurheartj\/ehv192","article-title":"Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design","volume":"36","author":"Mahfoud","year":"2015","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.pcad.2021.02.005_bb0150","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ahj.2015.08.021","article-title":"The SPYRAL HTN global clinical trial program: rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications","volume":"171","author":"Kandzari","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2021.02.005_bb0155","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ahj.2017.09.006","article-title":"A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: the RADIANCE-HTN and REQUIRE clinical study designs","volume":"195","author":"Mauri","year":"2018","journal-title":"Am Heart J"},{"issue":"7","key":"10.1016\/j.pcad.2021.02.005_bb0160","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacc.2014.03.059","article-title":"Anatomic assessment of sympathetic peri-arterial renal nerves in man","volume":"64","author":"Sakakura","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.pcad.2021.02.005_bb0165","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.jacc.2015.08.018","article-title":"Impact of lesion placement on efficacy and safety of catheter-based radiofrequency renal denervation","volume":"66","author":"Mahfoud","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.pcad.2021.02.005_bb0170","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jacc.2014.07.937","article-title":"Innervation patterns may limit response to endovascular renal denervation","volume":"64","author":"Tzafriri","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.pcad.2021.02.005_bb0175","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006196","article-title":"Blood pressure response to main renal artery and combined main renal artery plus branch renal denervation in patients with resistant hypertension","volume":"6","author":"Fengler","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"10108","key":"10.1016\/j.pcad.2021.02.005_bb0180","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(17)32281-X","article-title":"Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial","volume":"390","author":"Townsend","year":"2017","journal-title":"Lancet"},{"issue":"10137","key":"10.1016\/j.pcad.2021.02.005_bb0185","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","article-title":"Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial","volume":"391","author":"Kandzari","year":"2018","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.pcad.2021.02.005_bb0190","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1093\/eurheartj\/ehaa495","article-title":"Randomized trials of invasive cardiovascular interventions that include a placebo control: a systematic review and meta-analysis","volume":"41","author":"Lauder","year":"2020","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.pcad.2021.02.005_bb0195","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00392-020-01595-z","article-title":"Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED pivotal) and presence (SPYRAL HTN-ON MED expansion) of antihypertensive medicat","volume":"109","author":"B\u00f6hm","year":"2020","journal-title":"Clin Res Cardiol"},{"issue":"10234","key":"10.1016\/j.pcad.2021.02.005_bb0200","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","article-title":"Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED pivotal): a multicentre, randomised, sham-controlled trial","volume":"395","author":"B\u00f6hm","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.pcad.2021.02.005_bb0205","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jama.2019.9811","article-title":"Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes","volume":"322","author":"Yang","year":"2019","journal-title":"JAMA"},{"issue":"10137","key":"10.1016\/j.pcad.2021.02.005_bb0210","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","article-title":"Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial","volume":"391","author":"Azizi","year":"2018","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.pcad.2021.02.005_bb0215","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.119.040451","article-title":"Six-month results of treatment-blinded medication titration for hypertension control following randomization to endovascular ultrasound renal denervation or a sham procedure in the RADIANCE-HTN SOLO trial","volume":"139","author":"Azizi","year":"2019","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.pcad.2021.02.005_bb0220","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1016\/j.jcin.2020.09.054","article-title":"12-month results from the unblinded phase of the RADIANCE-HTN SOLO trial of ultrasound renal denervation","volume":"13","author":"Azizi","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"10.1016\/j.pcad.2021.02.005_bb0225","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.carrev.2015.04.008","article-title":"Next generation renal denervation: chemical \u201cperivascular\u201d renal denervation with alcohol using a novel drug infusion catheter","volume":"16","author":"Fischell","year":"2015","journal-title":"Cardiovasc Revascularization Med"},{"issue":"4","key":"10.1016\/j.pcad.2021.02.005_bb0230","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jcin.2019.10.048","article-title":"Alcohol-mediated renal denervation using the peregrine system infusion catheter for treatment of hypertension","volume":"13","author":"Mahfoud","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2021.02.005_bb0235","first-page":"93","article-title":"Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry","volume":"38","author":"Mahfoud","year":"2017","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.pcad.2021.02.005_bb0240","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1016\/j.jacc.2020.04.036","article-title":"Renal denervation in high-risk patients with hypertension","volume":"75","author":"Mahfoud","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.pcad.2021.02.005_bb0245","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1161\/HYPERTENSIONAHA.119.13019","article-title":"Renal denervation in isolated systolic hypertension using different catheter techniques and technologies","volume":"74","author":"Fengler","year":"2019","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.pcad.2021.02.005_bb0250","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/eurheartj\/ehy871","article-title":"Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial","volume":"40","author":"B\u00f6hm","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2021.02.005_bb0255","first-page":"1","article-title":"Ambulatory blood pressure monitoring to predict response to renal denervation","author":"Gosse","year":"2020","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.pcad.2021.02.005_bb0260","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/eurheartj\/ehu467","article-title":"Wilder\u2019s principle: pre-treatment value determines post-treatment response","volume":"36","author":"Messerli","year":"2015","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.pcad.2021.02.005_bb0265","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.jacc.2016.07.775","article-title":"Regression to the mean in SYMPLICITY HTN-3","volume":"68","author":"Pocock","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.pcad.2021.02.005_bb0270","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/eurheartj\/ehaa121","article-title":"Proceedings from the 3rd European clinical consensus conference for clinical trials in device-based hypertension therapies","volume":"41","author":"Mahfoud","year":"2020","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.pcad.2021.02.005_bb0275","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4244\/EIJ-D-19-00902","article-title":"Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation","volume":"16","author":"Townsend","year":"2020","journal-title":"EuroIntervention"},{"issue":"15","key":"10.1016\/j.pcad.2021.02.005_bb0280","first-page":"1211","article-title":"Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the global SYMPLICITY registry","volume":"40","author":"Mahfoud","year":"2019","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.pcad.2021.02.005_bb0285","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3390\/jcm8050581","article-title":"Relevance of targeting the distal renal artery and branches with radiofrequency renal denervation approaches\u2014a secondary analysis from a hypertensive CKD patient cohort","volume":"8","author":"Kiuchi","year":"2019","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.pcad.2021.02.005_bb0290","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.carrev.2018.05.011","article-title":"Comparison of standard renal denervation procedure versus novel distal and branch vessel procedure with brachial arterial access","volume":"20","author":"Petrov","year":"2019","journal-title":"Cardiovasc Revascularization Med"},{"issue":"2","key":"10.1016\/j.pcad.2021.02.005_bb0295","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/HJH.0000000000001160","article-title":"Denervation of the distal renal arterial branches vs. conventional main renal artery treatment","volume":"35","author":"Pekarskiy","year":"2017","journal-title":"J Hypertens"},{"issue":"5","key":"10.1016\/j.pcad.2021.02.005_bb0300","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/CIRCULATIONAHA.118.037654","article-title":"A three-arm randomized trial of different renal denervation devices and techniques in patients with resistant hypertension (RADIOSOUND-HTN)","volume":"139","author":"Fengler","year":"2019","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.pcad.2021.02.005_bb0305","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/j.jacc.2019.04.015","article-title":"Renal denervation update from the international sympathetic nervous system summit","volume":"73","author":"Kiuchi","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.pcad.2021.02.005_bb0310","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/jhh.2014.91","article-title":"Blood pressure response to renal nerve stimulation in patients undergoing renal denervation: a feasibility study","volume":"29","author":"Gal","year":"2015","journal-title":"J Hum Hypertens"},{"issue":"3","key":"10.1016\/j.pcad.2021.02.005_bb0315","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1161\/HYPERTENSIONAHA.116.07492","article-title":"Renal nerve stimulation-induced blood pressure changes predict ambulatory blood pressure response after renal denervation","volume":"68","author":"de Jong","year":"2016","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.pcad.2021.02.005_bb0320","doi-asserted-by":"crossref","first-page":"e1334","DOI":"10.4244\/EIJ-D-18-00536","article-title":"Safety and performance of diagnostic electrical mapping of renal nerves in hypertensive patients","volume":"14","author":"Tsioufis","year":"2018","journal-title":"EuroIntervention"},{"issue":"12","key":"10.1016\/j.pcad.2021.02.005_bb0325","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jcin.2019.04.047","article-title":"Transvascular pacing of aorticorenal ganglia provides a testable procedural endpoint for renal artery denervation","volume":"12","author":"Qian","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2021.02.005_bb0330","article-title":"A drug-induced hypotensive challenge to verify catheter-based radiofrequency renal denervation in an obese hypertensive swine model","author":"Lauder","year":"2020","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2021.02.005_bb0335","doi-asserted-by":"crossref","first-page":"37218","DOI":"10.1038\/srep37218","article-title":"Renal artery vasodilation may be an indicator of successful sympathetic nerve damage during renal denervation procedure","volume":"6","author":"Chen","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.pcad.2021.02.005_bb0340","first-page":"1","article-title":"The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up","author":"Bergland","year":"2020","journal-title":"Blood Press"},{"issue":"9917","key":"10.1016\/j.pcad.2021.02.005_bb0345","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0140-6736(13)62192-3","article-title":"Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study","volume":"383","author":"Krum","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pcad.2021.02.005_bb0350","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1253\/circj.CJ-18-1018","article-title":"Sufficient and persistent blood pressure reduction in the final long-term results from SYMPLICITY HTN-Japan: safety and efficacy of renal denervation at 3 years","volume":"83","author":"Kario","year":"2019","journal-title":"Circ J"},{"issue":"5","key":"10.1016\/j.pcad.2021.02.005_bb0355","doi-asserted-by":"crossref","first-page":"R353","DOI":"10.1152\/ajpregu.1980.238.5.R353","article-title":"Functional reinnervation and development of supersensitivity to NE after renal denervation in rats","volume":"238","author":"Kline","year":"1980","journal-title":"Am J Physiol Integr Comp Physiol"},{"issue":"2","key":"10.1016\/j.pcad.2021.02.005_bb0360","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1161\/HYPERTENSIONAHA.114.04176","article-title":"Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheter-based radiofrequency renal denervation in sheep","volume":"65","author":"Booth","year":"2015","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.pcad.2021.02.005_bb0365","doi-asserted-by":"crossref","first-page":"R675","DOI":"10.1152\/ajpregu.00599.2012","article-title":"Renal sensory and sympathetic nerves reinnervate the kidney in a similar time-dependent fashion after renal denervation in rats","volume":"304","author":"Mulder","year":"2013","journal-title":"Am J Physiol Integr Comp Physiol"},{"issue":"8","key":"10.1016\/j.pcad.2021.02.005_bb0370","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1097\/HJH.0000000000001798","article-title":"Regression of organ damage following renal denervation in resistant hypertension","volume":"36","author":"Kordalis","year":"2018","journal-title":"J Hypertens"},{"issue":"2","key":"10.1016\/j.pcad.2021.02.005_bb0375","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/HYPERTENSIONAHA.116.07464","article-title":"Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension","volume":"68","author":"Berra","year":"2016","journal-title":"Hypertension"},{"issue":"38","key":"10.1016\/j.pcad.2021.02.005_bb0380","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","article-title":"Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences","volume":"34","author":"Chowdhury","year":"2013","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.pcad.2021.02.005_bb0385","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ahj.2013.04.016","article-title":"Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease","volume":"166","author":"B\u00f6hm","year":"2013","journal-title":"Am Heart J"},{"issue":"8","key":"10.1016\/j.pcad.2021.02.005_bb0390","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jacc.2016.06.005","article-title":"Assessing the impact of medication adherence on long-term cardiovascular outcomes","volume":"68","author":"Bansilal","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.pcad.2021.02.005_bb0395","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/CIRCOUTCOMES.114.001240","article-title":"Quantifying the utility of taking pills for cardiovascular prevention","volume":"8","author":"Hutchins","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"12","key":"10.1016\/j.pcad.2021.02.005_bb0400","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s00392-019-01468-0","article-title":"Patient preference for therapies in hypertension: a cross-sectional survey of German patients","volume":"108","author":"Schmieder","year":"2019","journal-title":"Clin Res Cardiol"},{"issue":"48","key":"10.1016\/j.pcad.2021.02.005_bb0405","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1093\/eurheartj\/ehaa647","article-title":"Where is renal nerve ablation going?","volume":"41","author":"Lauder","year":"2020","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.pcad.2021.02.005_bb0410","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/HJH.0000000000002358","article-title":"Renal denervation in patients with end-stage renal disease and resistant hypertension on long-term haemodialysis","volume":"38","author":"Scalise","year":"2020","journal-title":"J Hypertens"},{"issue":"18","key":"10.1016\/j.pcad.2021.02.005_bb0415","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1161\/CIRCULATIONAHA.110.991869","article-title":"Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study","volume":"123","author":"Mahfoud","year":"2011","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.pcad.2021.02.005_bb0420","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/ejhf.502","article-title":"Renal denervation in heart failure with preserved ejection fraction (RDT-PEF): a randomized controlled trial","volume":"18","author":"Patel","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.pcad.2021.02.005_bb0425","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCRESAHA.115.302522","article-title":"Renal denervation for the treatment of cardiovascular high risk-hypertension or beyond?","volume":"115","author":"B\u00f6hm","year":"2014","journal-title":"Circ Res"},{"issue":"13","key":"10.1016\/j.pcad.2021.02.005_bb0430","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jacc.2012.05.036","article-title":"A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension","volume":"60","author":"Pokushalov","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.pcad.2021.02.005_bb0435","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jama.2019.21187","article-title":"Effect of renal denervation and catheter ablation vs catheter ablation alone on atrial fibrillation recurrence among patients with paroxysmal atrial fibrillation and hypertension","volume":"323","author":"Steinberg","year":"2020","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.pcad.2021.02.005_bb0440","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00392-016-1012-y","article-title":"Renal denervation for treatment of ventricular arrhythmias: data from an international multicenter registry","volume":"105","author":"Ukena","year":"2016","journal-title":"Clin Res Cardiol"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062021000190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062021000190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:17:19Z","timestamp":1758500239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062021000190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":88,"alternative-id":["S0033062021000190"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2021.02.005","relation":{},"ISSN":["0033-0620"],"issn-type":[{"type":"print","value":"0033-0620"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The current status of renal denervation for the treatment of arterial hypertension","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2021.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}